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Abstract
Introduction: Amyloid beta (Aβ) deposition was identified to precede tau pathol-
ogy and neurodegeneration in familial Alzheimer’s disease (AD). But the divergence
between sporadic and familial AD limits the extension of these findings to sporadic AD.
Methods: Longitudinal changes of biomarkers among different stages were assessed
using linear mixed-effects models. The slopes of the models were used to estimate
rates of change to calculate the biomarker trajectories in sporadic AD.
Results: Cerebrospinal fluid (CSF) Aβ was estimated to decline 45.2 years (abnormal:
27.8 years) before dementia, and Aβ deposition seemed to increase 31.7 years (abnor-
mal: 26.7 years) before dementia. It was estimated to take 29.0 years (CSF t-tau), 12.2
years (memory), 11.6 years (hippocampus), 9.3 years (hypometabolism), and 6.1 years
(cognition) tomove from normal to dementia.
Discussion: The trajectory in sporadic AD is led by Aβ accumulation, followed by CSF
t-tau increase, memory deficits, brain atrophy, hypometabolism, and cognitive decline.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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1 BACKGROUND
Alzheimer’s disease (AD) is a neurodegenerative disorder clinically
characterized by early memory loss and progressing into dementia.1 It
has been documented that amyloid beta (Aβ) deposition, tau pathology,
andneuronal degenerationprecede clinical symptoms.2-6 The longpre-
clinical phase of AD is an opportunity to identify the changes in patho-
physiological biomarkers that might improve diagnosis and prognosis,
and offer the opportunity for prevention trials.7-10 Establishment of
a dynamic model of biomarkers of AD is important for improving the
design of clinical treatment trials and developing new effective inter-
ventions.
To date, cross-sectional and longitudinal data in autosomal domi-
nant AD identified that Aβ deposition emerged as an upstream event
in the pathogenesis of AD andwas associatedwith downstream patho-
physiologic changes (ie, tau pathology andneurodegeneration).11-18 Aβ
has been observed to aggregate and accumulate in the brain in the pre-
clinical phaseofADuntil a critical threshold is reached,with a sigmoidal
trajectory characterized by rapid progression and finally a plateau.19
A significant portion of the published data on AD progression is based
on autosomal dominant AD, and the extension to sporadic AD remains
to be verified, a task complicated by mixed pathology due to non-AD
pathologic change and aging in elderly individuals.1,20
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) observa-
tional study enrolled a large cohort of sporadic AD (preclinical AD,
prodromal AD, and dementia due to AD) collecting longitudinal cere-
brospinal fluid (CSF) proteins (Aβ, t-tau, and p-tau), neuroimaging
measurements, and cognitive functions at assessments separated by
approximately a year.21 Here, we compared the levels and the change
rates of in vivo biomarkers among the three stages (preclinical AD, pro-
dromal AD, and dementia due to AD), and attempted to describe in this
longitudinal study the clinical and biomarker trajectories in sporadic
AD.
2 METHODS
2.1 ADNI dataset
ADNI is a large,multicenter, longitudinal neuroimaging study, launched
in 2003 by the National Institute on Aging, the National Institute of
Biomedical Imaging and Bioengineering, the Food and Drug Adminis-
tration, pharmaceutical companies, and nonprofit organizations.21 The
studywas approved by the institutional review boards of all participat-
ing centers and written informed consent was obtained from all par-
ticipants or authorized representatives after extensive description of
the ADNI based on the 1975 Declaration of Helsinki. The participants
in this study were from the ADNI database (http://adni.loni.usc.edu).
Inclusion criteria for AD subjects included National Institute of
Neurological and Communication Disorders/Alzheimer’s Disease and
Related Disorders Association criteria for probable AD (NINCDS–
ADRDA)22 with a Mini-Mental State Examination (MMSE) score
between 20 and 26, a global Clinical Dementia Rating (CDR) of 0.5
or 1, and a sum-of-boxes Clinical Dementia Rating (CDR-SB) of 1.0 to
9.0. All amnestic mild cognitive impairment (aMCI) subjects fulfilled
a MMSE score of 24 to 30 and a Memory Box score of at least 0.5.
Participants who had any serious neurological disease other than pos-
sible AD, any history of brain lesions or head trauma, or psychoac-
tive medication use were excluded from this study. Details of the
ADNI cohort can be foundonline (http://adni.loni.usc.edu/wp-content/
uploads/2010/09/ADNI_GeneralProceduresManual.pdf).
2.2 CSF proteins examination
The data regarding CSF proteins were obtained from “UPENN CSF
Biomarker Master [ADNI1, GO, 2] Version 2016-07-05.csv” online
(http://loni.usc.edu/). The detailed methods of measurement of CSF
proteins test are described elsewhere.23 Based on the National Insti-
tute on Aging-Alzheimer’s Association (NIA-AA) criteria, a cutoff value
was necessary to categorize theAβ1-42 concentrations into normal and
abnormal levels. Based on Shawet al.,24,25 a cutoff value for CSFAβ1-42
≤192 pg/mLwas used to identify an abnormal level.
2.3 Neuroimaging methods
The positron emission tomography (PET) imaging data with amyloid
tracer, florbetapir (AV-45), were from the UC Berkeley–AV45 analysis
dataset (“UC Berkeley - AV45 Analysis [ADNIGO, 2] Version 2020-05-
12.csv”) available online (http://adni.loni.usc.edu/). The native-space
magnetic resonance imaging (MRI) scan for each participant was
segmented with Freesurfer (version 4.5.0) to define cortical gray
matter regions of interest (ROI; frontal, anterior/posterior cingulate,
lateral parietal, lateral temporal) that make up a summary cortical ROI.
A composite reference region was defined as reference region. Each
florbetapir scan was applied to the corresponding MRI and the mean
florbetapir uptake calculated within the cortical and reference region.
Finally, florbetapir standard uptake value ratios (SUVRs) were created
by averaging across the four cortical regions and dividing this cortical
summary ROI by the reference region. A cutoff value of 0.79 defined
positive or negative amyloid.
The MRI data were extracted from the dataset (“UCSF – cross-
Sectional FreeSurfer (5.1) [ADNI1, GO, 2] Version 2019-11-08.csv”),
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and measurements of cerebral metabolic fluorodeoxyglucose
PET (FDG-PET) were downloaded from the dataset (“UC Berke-
ley – FDG Analysis [ADNI1, GO, 2] Version 2020-05-28.csv”) in
the ADNI dataset. A detailed description of the acquisition and
processing of the imaging data from ADNI has been previously
described.26 In this study, we used hippocampal atrophy as a MRI-
related marker and cerebral metabolism rate for glucose (CMRgl)
of the bilateral posterior cingulate as FDG-PET markers for our
analysis.
2.4 Cognitive assessment
To assess memory function, we used a composite memory score from
the database “UW–Neuropsych Summary Scores [ADNI1, GO, 2] Ver-
sion 2020-03-26.csv” available online (http://adni.loni.usc.edu/). This
was a weighted score based on memory items in the Rey Auditory
Verbal Learning Test (RAVLT), the Alzheimer’s Disease Assessment
Scale-Cognitive (ADAS-cog), the MMSE, and Logical Memory. In addi-
tion, the CDR-SB score was used to evaluate general cognition and
the CDR-SB score was extracted from the merged ADNI database
(“ADNIMERGE.csv”).
2.5 Statistical analysis
Based on the NIA-AA criteria, the ADNI participants were divided into
four groups. Because the Aβ markers have a higher specificity than
did other markers in the diagnosis of AD, only Aβ markers (CSF Aβ
or amyloid imaging) were used for categorization.1 Dementia due to
AD required meeting criteria for dementia and positive Aβ markers
(either decreased Aβ1-42 in CSF or elevated SUVR on amyloid PET).
MCI due to AD required mild cognitive impairment and abnormal Aβ
markers. Both preclinical AD and healthy controls required normal
cognitive function, whereas preclinical AD also required positive Aβ
markers.
Baseline differences between the four groups were analyzed using
one-way analysis of variance (ANOVA) for continuous variables and
Pearson chi-square analysis for categorical variables. The Tukey
honestly significant difference (HSD)methodwas used to evaluate dif-
ferences between two groups in post hoc analyses. A within-subjects
linear mixed-effects model with data from at least two visits was
used to assess how clinical and biomarkers changed over time in the
four groups, with fixed effects of age, sex, time, years of education,
and apolipoprotein E (APOE ε4) status, and random effects of random
intercepts and slopes (see supporting information). The time intervals
to progress to the next stage were estimated based on the differences
between themean values of different stages and the rates of change of
variables in the longitudinal study. All models were fittedwith the lmer
function in the lme4 package in R, version 3.1.3. Estimates and upper
and lower quartiles were based on parametric bootstrapping of the
fittedmodel by use of the sim function in the arm package, with 10,000
replicates.
Research in context
1. Systematic review: We reviewed available English lan-
guage literature in PubMed for the clinical and biomarker
changes in Alzheimer’s disease (AD). It has beenwell doc-
umented that amyloid beta (Aβ) deposition, tau pathol-
ogy, and neuronal degeneration precede clinical symp-
toms in autosomal dominant AD. Because the diver-
gence on pathogenesis between sporadic and familial
AD significantly limits the extension of these findings
to sporadic AD, the dynamic model of biomarkers in
sporadic AD remains to be further characterized and
is of great importance to clinical understanding and
management.
2. Interpretation: Our findings identified that the trajectory
of biomarkers in sporadic AD is led by Aβ accumula-
tion; followed by CSF t-tau increase, memory deficits,
brain atrophy, hypometabolism; and last, cognition
decline.
3. Future directions: Learning the trajectories of biomarkers
in sporadic ADwill be imperative to evaluating the devel-
opment and progression of AD, and beneficial for screen-
ing participants in AD clinical trials.
3 RESULTS
3.1 Study participants
From the 1735 subjects in the ADNI database, 1215 subjects under-
went CSF Aβ examination or amyloid imaging test (Figure 1). Based
on the 2011 NIA-AA criteria, 167 subjects who presented normal cog-
nitive function and negative Aβ markers in CSF or amyloid imaging
test were classified as healthy controls, and 133 patients with preclin-
ical AD had normal cognitive function and abnormal Aβ burden. The
MCI due to AD group (n = 451) showed mild cognitive impairment
on cognition assessment and abnormal Aβ burden, and the dementia
due to AD patients (n = 231) met dementia criteria on the cognitive
assessment, and also had evidence of Aβ pathology in CSF or amyloid
imaging.
The demographic characteristics of the included subjects are listed
in Table S1A in supporting information. The healthy controls, preclini-
cal AD, MCI due to AD, and dementia due to AD patients significantly
differed on age, sex, and education years. The frequency of APOE ε4
carriers was higher in dementia due to AD, MCI due to AD, and pre-
clinical AD patients than in healthy controls. The four groups differed
significantly on CSF proteins (Aβ1-42, t-tau, and p-tau181) levels, Aβ
deposition on amyloid imaging, hippocampal atrophy on MRI, cerebral
hypometabolism on FDG-PET, and cognitive assessment at baseline
(P< .01; Table S1A).
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F IGURE 1 Classification of Alzheimer’s Disease Neuroimaging Initiative subjects. Aβ, amyloid beta; AD, Alzheimer’s disease; MCI, mild
cognitive impairment; CSF, cerebrospinal fluid; Aβmarker including CSF Aβ and amyloid imaging
3.2 CSF proteins
Our study included 521 subjects who underwent at least two CSF
tests. The levels of CSF proteins and their annual rate of change among
the groups are listed in Table S1A and Table S2B in supporting informa-
tion. The difference in CSF Aβ1-42 between preclinical AD patients and
healthy controls was significantly larger than that between MCI due
to AD and preclinical AD, and that between dementia due to AD and
MCI due to AD (Figure 2A, Table S1B, and Table S3A–C in supporting
information). It indicated that the decrease of Aβ1-42 in CSF primarily
occurred during the progression from normal cognition to preclin-
ical AD (Figure 3A), and it was estimated to take 32.6 (25th–75th:
25.7–44.4) years, 5.2 (25th–75th: 3.8–8.5) years, and 7.4 (25th–75th:
6.4–8.9) years to change from healthy controls to preclinical AD, from
preclinical AD toMCI due to AD, and fromMCI due to AD to dementia
due to AD, respectively (Figure 3A). Anchoring of the curve at the
192 pg/mL (cutoff value) showed that it may take 17.6 (25th–75th:
13.9–24.0) years to transition from 241.87 pg/mL (healthy controls)
to below the cutoff of 192 pg/mL (Figure 2A). Both of these sets of
evidence indicated the whole span of the CSF Aβ1-42 to transition from
normal level to dementia due to AD was 45.2 years, and CSF Aβ1-42
was initially abnormal 27.8 years before the onset of dementia.
We noted a significantly higher level of CSF tau (t-tau and p-tau181)
in preclinical AD than in healthy controls, and a higher tau level in MCI
due to AD than in the preclinical AD group (P < .05) (Table S4A-C and
Table S5A-C in supporting information), but CSF tau in patients with
dementia due toADdid not differ from that in patientswithMCI due to
AD (Figure2B-C, Table S1B). It suggested that the increased rateofCSF
tau slowed as AD progressed. The time interval was about 23.4 (25th–
75th: 18.8–31.1) years for CSF t-tau to increase from normal level to
the level of MCI due to AD, and 5.6 (25th–75th: 4.7–7.0) years from
MCIdue toADtodementiadue toAD (FigureS1 in supporting informa-
tion). Thus, the whole span of CSF t-tau to increase from normal level
to dementia due to ADwas about 29.0 years.
3.3 Amyloid imaging
There were 461 subjects with amyloid imaging who met our inclu-
sion criteria. The SUVRs on amyloid imaging and their annual rates
of change are listed in Tables S1A and S2A. We noted that the SUVR
on amyloid imaging increased with disease progression (Figure 2D).
Patients with preclinical AD had a faster rate of Aβ deposition than did
healthy controls (P < .05; Table S2B, and Table S6A–C in supporting
information). Anchoring of the curve at the 0.79 SUVR (cutoff value), it
was estimated to take 5.0 (25th–75th: 4.7–5.4) years to progress from
0.74 SUVR (healthy controls) to 0.79 SUVR (Figure 3B). Furthermore,
it was estimated to take 22.6 (25th–75th: 21.0–24.5) years to increase
from 0.74 SUVR (healthy controls) to 0.95 SUVR (MCI due to AD), and
9.1 (25th–75th: 8.5–9.7.5) years to increase from 0.95 SUVR (MCI due
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F IGURE 2 Biomarkers at baseline and in the longitudinal study. A, CSF Aβ. Lope (Dementia due to AD: –0.045,MCI due to AD: –1.26,
Preclinical AD: –0.126, Healthy controls: –2.00, P= .617). B, CSF t-tau. Lope (Dementia due to AD: 1.45,MCI due to AD: 2.93, Preclinical AD: 3.63,
Healthy controls: 1.07, P=.558). C, CSF p-tau. Lope (Dementia due to AD: 3.03,MCI due to AD: 3.94, Preclinical AD: 3.36, Healthy controls: 1.40,
P=.458). D, Amyloid imaging (SUVR). Lope (Dementia due to AD: 0.009,MCI due to AD: 0.008, Preclinical AD: 0.010, Healthy controls: 0.003, P<
.01). E, CMRgl (FDG-PET). Lope (Dementia due to AD: –0.06,MCI due to AD: –0.03, Preclinical AD: –0.02, Healthy controls: -0.01, P< .01. F,
Hippocampus. Lope (Dementia due to AD: –139.88,MCI due to AD: –98.12, Preclinical AD: –67.23, Healthy controls: –47.25, P=.02. G, Composite
Memory. Lope (Dementia due to AD: –0.23,MCI due to AD: –0.16, Preclinical AD: –0.04, Healthy controls: –0.01, P< .01. H, CDR-SB. Lope
(Dementia due to AD: 1.8, MCI due to AD: 0.70, Preclinical AD: 0.15, Healthy controls: 0.06, P< .01). Aβ, amyloid beta; AD, Alzheimer’s disease;
CDR-SB, Clinical Dementia Rating scale Sum of Boxes; CMRgl, cerebral metabolism rate for glucose on FDG-PET
(fluorodeoxyglucose-positron-emission tomography); CSF, cerebrospinal fluid; MCI, mild cognitive impairment; SUVR, standard uptake value
ratios on amyloid imaging;.
to AD) to 1.02 SUVR (dementia due to AD). Thus, the entire time span
of Aβ deposition to progress from healthy controls to dementia due to
ADwas 31.7 years, and SUVR on imaging became abnormal 26.7 years
before the onset of symptoms.
3.4 Glucose metabolism
In the current study, 519 subjects underwent at least two FDG-PET
tests. The CMRgl on FDG-PET and their annual rates of change are
shown in Tables S1A and S2A. The CMRgl on FDG-PET decreased
with disease progression (Table S1B), and dementia due to AD patients
showed the fastest rateofCMRgl decline among the four groupsduring
follow-up (P < .05; Figure 2E, Table S2B and Table S7A–C in support-
ing information). This suggested the decrease of cerebral metabolism
accelerated as disease progressed. Furthermore, it was estimated to
take3.8 (25th–75th: 3.6–4.2) years todecline from1.41CMRgl (heathy
controls) to 1.32 CMRgl (MCI due to AD), and 5.5 (25th–75th: 5.2–5.8)
years to decline from1.32CMRgl to 1.16CMRgl (dementia due to AD),
which indicated it was estimated to take 9.3 years to decrease from
normal levels to the level of dementia due to AD (Figure 2).
3.5 Hippocampal atrophy
In this study, 626 subjects were assessed at least twice using MRI. The
size of the hippocampus and the annual rate of change are shown in
Tables S1A and S2A. The volume of hippocampus decreased with dis-
ease progression (Table S1B), and patients with dementia due to AD
had a higher hippocampal atrophy rate than did the other three groups
in the longitudinal study (Figure 2F, Table S2B and Table S8A–C in sup-
porting information). These results indicated the atrophy of the hip-
pocampus accelerated as disease progressed. The time intervalwas 6.2
(25th–75th: 5.7–6.7) years for hippocampus decrease from 3836mm3
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F IGURE 3 The dynamic change of Aβmarkers in sporadic Alzheimer’s disease. A, The change of Aβ in CSF. The time interval for CSF Aβ to
transition from healthy controls to preclinical AD, from preclinical AD toMCI due to AD, and fromMCI due to AD to dementia due to AD, was 32.6
(25th–75th: 25.7–44.4) years, 5.2 (25th–75th: 3.8–8.5) years, and 7.4 (25th-=75th: 6.4–8.9) years, respectively. The time interval for CSF Aβ to
transition from the level of healthy controls to cutoff value was 17.8 (25th–75th: 14.1–24.3) years. B, The change of Aβ deposition on amyloid
imaging. The time interval to transition from healthy controls toMCI due to AD, and fromMCI due to AD to dementia due to AD, was 22.6
(25th–75th: 21.1–24.5) years, and 9.1 (25th–75th: 8.5–9.7) years, respectively. The time interval for CSF Aβ to transition from the level of healthy
controls to cutoff valuewas 5.0 (25th–75th: 4.7–5.4) years. Aβ, amyloid beta; AD, Alzheimer’s disease; CSF, cerebrospinal fluid;MCI, mild cognitive
impairment; SUVR, standard uptake value ratios on amyloid imaging.
(healthy controls) to 3431 mm3 (MCI due to AD), and 5.4 (25th–75th:
5.2–5.6) years to decrease from 3431 to 2947 mm3 (dementia due to
AD), suggesting the whole span of the hippocampus to decrease from
normal level to the level of dementia was 11.6 years (Figure 3).
3.6 Cognitive assessments
Here, 946 and 949 subjects received CDR-SB andmemory assessment
at least twice, respectively. Patients with preclinical AD did not differ
from healthy controls on CDR-SB or memory assessment at baseline
or on their change rates in follow-up. We noted a worse performance
on memory and cognition assessment in patients with dementia due
to AD than those with MCI due to AD and preclinical AD (Table S1A–
B). Similarly, patients with dementia due to AD had a faster rate of
cognition decline than did patients with MCI due to AD and preclini-
cal AD (Figure 2G–H, Table S2A-B, Table S9A–C, and Table S10A–C in
supporting information). Both of these results indicated that memory
and cognitive functionmostly declined during theMCI due to AD stage
before the onset of dementia, and the decrease in memory and cogni-
tion accelerated as disease progressed. It was estimated to take 12.2
years for memory, and 6.1 years for cognition to change from the aver-
age level of healthy controls to that of dementia due to AD.
3.7 Combined model
Our study showed that Aβ deposition occurred first during the whole
course of AD. It was estimated to take 45.2 years for CSF Aβ, and 31.7
years for amyloid imaging to change from the level of healthy controls
to the level of dementia due to AD. Moreover, the Aβ biomarker began
to be abnormal 27.8 years (for CSF) and 26.7 years (for amyloid imag-
ing) before the onset of dementia. Then, CSF t-tau started to increase,
followed by memory impairment, hippocampal atrophy, and cerebral
metabolism decline, and it was estimated to take 29.0 years for CSF t-
tau, 12.2 years for memory, 11.6 years for hippocampus volume, and
9.3 years for cerebral metabolism to change from normal levels to the
levels of dementia due to AD. The general cognition declined with a
time interval of 6.1 years for CDR-SB to arrive at the level of demen-
tia due to AD from the normal level (Figure 4).
4 DISCUSSION
The 2011 NIA-AA criteria for AD have incorporated biomarkers in the
diagnosis ofADandexpanded coverage of disease stages, frompreclin-
ical AD andMCI due toAD to dementia due toAD.1,27 According to the
new2018NIA-AA framework forAD,28 Aβwas theessential biomarker
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F IGURE 4 Sequence of biomarkers changes in Alzheimer’s Disease Neuroimaging Initiative subjects. AD, Alzheimer’s disease; CDR-SB,
Clinical Dementia Rating scale Sum of Boxes; CMRgl, cerebral metabolism rate for glucose on FDG-PET (fluorodeoxyglucose-positron-emission
tomography); CSF, cerebrospinal fluid; SUVR, standard uptake value ratios on amyloid imaging. Composite memory is a weighted score based on
memory items in Rey Auditory Verbal Learning Test, the Alzheimer’s Disease Assessment Scale-Cognitive, theMini-Mental State Examination, and
Logical Memory.
for theADcontinuum. In the current study,we reclassified the included
subjects with the Aβ assessment into four groups: healthy controls,
preclinical AD, MCI due to AD, and dementia due to AD groups. The
four groups differed significantly on the levels of clinical markers and
biomarkers. In the dynamic model, CSF Aβ decreased first, followed by
amyloid imaging, and the change rates of Aβ markers slowed down as
AD progressed. When the levels of Aβ approached the threshold, CSF
t-tau was observed to increase; sequentially, memory function, hip-
pocampal size, and cerebral metabolism began to decrease, and their
change rates accelerated as the disease progressed. Finally, general
cognition started to decline as dementia onset approached (Figure 5).
These findings identified the temporal occurrence of Aβ accu-
mulation, CSF t-tau increase, memory deficits, brain atrophy,
hypometabolism, and cognitive decline in sporadic AD. Our study
provided novel evidence for the hypothetical model of biomarkers
based on sporadic AD pathological cascade established by Jack et al.2
and Sperling et al.7 Furthermore, we estimated the time interval for
clinical and biomarkers to transition from normal level to the level
of dementia due to AD based on the ADNI data. It may be useful
to estimate the time interval for a patient with high risk for AD to
archive the level of dementia, which was beneficial to assess disease
severity, and screen the appropriate participants in clinical trials for
AD.
Our current study supported Aβ deposition as the first phase of the
natural history of sporadic AD. The time interval was 45.2 years for
CSFAβ and 31.7 years for amyloid imaging to reach the level of demen-
tia from normal, respectively. This identified that CSF Aβ1-42 decrease
emerges prior to amyloid imaging,29 which confirmed the findings that
CSF Aβ1-42 becomes abnormal before amyloid PET in sporadic AD,30
and was consistent with the results from the longitudinal study in
the Dominantly Inherited Alzheimer Network (DIAN) cohort.13 More-
over, our study observed that the annual rate of change of CSF Aβ
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F IGURE 5 The trajectories of biomarkers in sporadic Alzheimer’s disease. CDR-SB, Clinical Dementia Rating scale Sum of Boxes; CMRgl,
cerebral metabolism rate for glucose on FDG-PET (fluorodeoxyglucose-positron-emission tomography); CSF, cerebrospinal fluid; SUVR, standard
uptake value ratios on amyloid imaging. Composite memory is a weighted score based onmemory items in Rey Auditory Verbal Learning Test, the
Alzheimer’s Disease Assessment Scale-Cognitive, theMMSE and LogicalMemory.
reduced as AD progressed, which supports Aβ accumulation progress-
ing with a sigmoid-shaped trajectory as a plausible course of sporadic
AD.19,31
Comparing our results to the findings from DIAN,13 the dynamic
changes of Aβ accumulation and tau pathology in sporadic AD
were notably similar to those in autosomal dominant AD, sug-
gesting that sporadic AD and familial AD may share similar basic
mechanisms irrespective of the different pathogenic pathways.13
Moreover, the trajectories of glucose metabolism and hippocampal
atrophy in ADNI were comparable to those obtained from the data
in DIAN, and earlier than that in the Australian Imaging, Biomark-
ers and Lifestyle (AIBL) study.32 Inconsistency in data acquisition
or analysis methods may account for some of the discrepancy.
However, our analysis demonstrated that memory deficits occur
before global cognitive impairment,33,34 and even prior to glucose
hypometabolism or brain atrophy, which was partially in agreement
with the hypothetical model.2,3 Aβ accumulation early in the disease
affects hypoconnectivity in brain, but not brain atrophy or glucose
hypometabolism.35
The dynamic model of biomarkers must also be interpreted with
caution. Unlike autosomal dominant AD, not all sporadic AD in the pre-
clinical stage will progress into dementia. Thus, our findings represent
population rather than individual trajectories, and it was essential to
validate this model in an independent cohort. Moreover, the included
participants only had a limited follow-up and the time period may be
too short to capture the whole course of AD. Follow-up throughout
the entire disease course would, of course, be ideal, but extremely
challenging to achieve practically. Other vulnerabilities, such as age,
education, genetic susceptibility, and lifestyle, may also contribute
to the trajectories of biomarkers in sporadic AD development.36-38
Furthermore, a positive amyloid test (CSF or PET) was needed to
define AD based on the current evidence, but it limited us to make
any inferences on where amyloid comes in the dynamic model of
AD by making AD contingent on a positive amyloid test, and limits
our claims about temporal ordering to other biomarkers and clinical
tests.
5 CONCLUSIONS
In summary, the data from the ADNI cohort revealed the trajectory of
biomarkers in sporadic AD with the sequence of Aβ accumulation, fol-
lowed by CSF t-tau, then memory deficits preceding hypometabolism
and brain atrophy, and finally cognitive decline. This dynamic model
provides insights into the progression of AD and facilitates the selec-
tion of participants and endpoints in clinical trials.
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